DexCom, Inc. (NASDAQ:DXCM) EVP Sells $318,275.07 in Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Sadie Stern also recently made the following trade(s):

• On Monday, September 9th, Sadie Stern sold 426 shares of DexCom stock. The shares were sold at an average price of $69.15, for a total value of $29,457.90.

DexCom Price Performance

Shares of DexCom stock traded down $1.63 during midday trading on Friday, hitting $72.83. 4,451,148 shares of the company traded hands, compared to its average volume of 3,927,169. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The stock has a market cap of $28.45 billion, a price-to-earnings ratio of 44.60, a PEG ratio of 2.30 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The firm’s fifty day moving average price is $70.54 and its 200-day moving average price is $90.23.

Institutional Investors Weigh In On DexCom

Institutional investors and hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC grew its holdings in DexCom by 40.3% in the first quarter. Acadian Asset Management LLC now owns 8,008 shares of the medical device company’s stock worth $1,109,000 after purchasing an additional 2,299 shares during the period. Clearbridge Investments LLC lifted its stake in DexCom by 29.8% during the 1st quarter. Clearbridge Investments LLC now owns 38,958 shares of the medical device company’s stock valued at $5,403,000 after acquiring an additional 8,936 shares in the last quarter. Natixis lifted its position in shares of DexCom by 25.0% during the first quarter. Natixis now owns 8,000 shares of the medical device company’s stock valued at $1,110,000 after purchasing an additional 1,600 shares in the last quarter. Crewe Advisors LLC bought a new stake in DexCom in the 1st quarter worth about $29,000. Finally, Advisors Asset Management Inc. lifted its position in shares of DexCom by 13.9% during the 1st quarter. Advisors Asset Management Inc. now owns 14,800 shares of the medical device company’s stock worth $2,053,000 after buying an additional 1,809 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

DXCM has been the topic of several recent research reports. Piper Sandler reiterated an “overweight” rating and set a $90.00 target price on shares of DexCom in a research report on Monday, August 26th. Sanford C. Bernstein upped their target price on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. BTIG Research cut their target price on shares of DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Stifel Nicolaus lifted their price target on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, August 23rd. Finally, Oppenheimer dropped their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.